Importantly, RHAMM-targeted peptide vaccines such as the RHAMM-R3 epitope have emerged as promising immunotherapeutic approaches, capable of inducing strong CD8+ T-cell responses, particularly in hematologic malignancies, and enhancing graft-versus-leukemia effects. The gene discussed is HMMR; the disease is hematologic disorder.